|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 74.14 EUR | +1.09% |
|
-3.20% | -10.37% |
| 06-19 | Sanofi Receives Approval for Sarclisa Subcutaneous Formulation in Japan for Multiple Myeloma | CI |
| 06-19 | Japan gives the green light to Sanofi's Sarclisa SC in multiple myeloma |  |
Evolution of the Average Target: Sanofi
Evolution of the Target Price: Sanofi
Changes in Analyst Recommendations: Sanofi
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +30.43% | |||||
| +10.94% | |||||
| +10.72% | |||||
| +17.12% | |||||
| +12.21% | |||||
| +26.26% | |||||
| +5.72% | |||||
| +7.33% | |||||
| +4.49% | |||||
| +27.32% | |||||
| Average | +15.25% | |||||
| Weighted average by Cap. | +13.29% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| CIC Corporate & Institutional Banking | |
| JEFFERIES | |
| Morgan Stanley | |
| JPMORGAN | Richard Vosser |
| BERNSTEIN RESEARCH | Justin Smith |
| UBS | Matthew Weston |
| alphavalue | Abhishek Raval |
| BARCLAYS | James Gordon |
| BNP Paribas | |
| BERENBERG | |
| GOLDMAN SACHS | James Quigley |
| DEUTSCHE BANK RESEARCH | Emmanuel Papadakis |
| AlphaValue/Baader Europe | |
| Bank of America Securities/Merrill Lynch | |
| Guggenheim | |
| DZ BANK | Elmar Kraus |
| Intron Health | |
| Berenberg Bank | |
| CIC Market Solutions | |
| STIFEL | Eric Le Berrigaud |
| CREDIT SUISSE | Dominic Lunn |
| Argus | |
| Kepler Cheuvreux | |
| DEUTSCHE BANK | Emmanuel Papadakis |
| Stifel Nicolaus | |
| Liberum Capital | |
| SVB Leerink | |
| BAADER BANK | |
| Deutsche Bank Securities | |
| ODDO BHF | |
| HSBC | Julie Mead |
| BANK OF AMERICA (BOFA) | Sachin Jain |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
- Consensus Sanofi
Select your edition
All financial news and data tailored to specific country editions
